Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

OR3A4 was upregulated in DLBCL and tied to poor prognosis

Publish date:: June 22, 2020

Key clinical point: DLBCL patients with high OR3A4 expression suffered from poor prognosis.

Major finding: FOXM1-induced upregulation of OR3A4 enhances DLBCL via Wnt/beta-catenin signaling.

Study details: Genetic study of tissue specimens from DLBCL patients and DLBCL cell lines.

Disclosures: The authors declared that they had no competing interests.

Citation:

Meng H et al. Experimental and Molecular Pathology. 2020;115:doi.org/10.1016/j.yexmp.2020.104451.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in DLBCL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

Survey quantifies COVID-19’s impact on oncology,

Sarcopenia is a predictor of overall survival in DLBCL patients,

Mutation tied to central nervous system collapse in DLBCL,